151 related articles for article (PubMed ID: 36625510)
1. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Unger JM; Qian L; Redman MW; Tavernier SS; Minasian L; Sigal EV; Papadimitrakopoulou VA; Leblanc M; Cleeland CS; Dzingle SA; Summers TJ; Chao H; Madhusudhana S; Villaruz L; Crawford J; Gray JE; Kelly KL; Gandara DR; Bazhenova L; Herbst RS; Gettinger SN; Moinpour CM
J Natl Cancer Inst; 2023 Apr; 115(4):437-446. PubMed ID: 36625510
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
3. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Cheng Y; Sakai H; Paz-Ares L; Lu S; John T; Sun X; Moisei A; Taylor F; Lawrance R; Zhang X; Sylvester J; Yuan Y; Blum SI; Penrod JR; Carbone DP
Eur J Cancer; 2023 Apr; 183():174-187. PubMed ID: 36871487
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
8. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Reyes F; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; Paz-Ares L; Carbone DP; Memaj A; Marimuthu S; Zhang X; Tran P; John T
ESMO Open; 2021 Oct; 6(5):100273. PubMed ID: 34607285
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T; Sakai H; Ikeda S; Cheng Y; Kasahara K; Sato Y; Nakahara Y; Takeda M; Kaneda H; Zhang H; Maemondo M; Minato K; Hisada T; Misumi Y; Satouchi M; Hotta K; Li A; Oukessou A; Lu S
Int J Clin Oncol; 2022 Apr; 27(4):695-706. PubMed ID: 35182247
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
14. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
17. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO; Grün CB; Niegisch G; Pichler M; Roghmann F; Schmitz-Dräger B; Baretton G; Schmitz M; Bolenz C; Foller S; Leucht K; Schumacher U; Schostak M; Meran J; Loidl W; Zengerling F
Lancet Oncol; 2023 Apr; 24(4):347-359. PubMed ID: 36868252
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.
Ebert MP; Meindl-Beinker NM; Gutting T; Maenz M; Betge J; Schulte N; Zhan T; Weidner P; Burgermeister E; Hofheinz R; Vogel A; Angermeier S; Bolling C; de Wit M; Jakobs R; Karthaus M; Stocker G; Thuss-Patience P; Leidig T; Gaiser T; Kather JN; Haertel N
Lancet Healthy Longev; 2022 Jun; 3(6):e417-e427. PubMed ID: 36098320
[TBL] [Abstract][Full Text] [Related]
19. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO; Hasanov E; Cao HST; Xiao L; Vauthey JN; Lee SS; Yavuz BG; Mohamed YI; Qayyum A; Jindal S; Duan F; Basu S; Yadav SS; Nicholas C; Sun JJ; Singh Raghav KP; Rashid A; Carter K; Chun YS; Tzeng CD; Sakamuri D; Xu L; Sun R; Cristini V; Beretta L; Yao JC; Wolff RA; Allison JP; Sharma P
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):208-218. PubMed ID: 35065057
[TBL] [Abstract][Full Text] [Related]
20. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
